H. Esteban

发表

Response to Combined Antiretroviral Therapy According to Gender and Origin in a Cohort of Naïve HIV-Infected Patients: GESIDA-5808 Study

J. Pérez-Molina, P. Domingo, I. Suárez-Lozano, 2012, HIV clinical trials.

Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

J. Mallolas, C. Quereda, F. Pulido, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Eradication of hepatitis C virus and non‐liver‐related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection

C. Tural, J. Mallolas, M. Crespo, 2017, Hepatology.

Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.

A. López-Guillermo, J. Ribera, J. Navarro, 2007, Haematologica.

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

D. Podzamczer, E. Ribera, S. Moreno, 2016, PloS one.

Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients

M. Salavert, J. Navarro, A. Curran, 2020, Clinical Infectious Diseases.

Effects of HCV Eradication on Bone mineral density in HIV/HCV Coinfected Patients.

E. Martinez, J. Navarro, C. Quereda, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen

A. López-Guillermo, J. Ribera, J. Navarro, 2009, Leukemia & lymphoma.

Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant

J. Losa, J. Bisbe, S. Reus, 2018, Open forum infectious diseases.

Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion.

E. Negredo, E. Martinez, J. De La Torre, 2021, The Journal of antimicrobial chemotherapy.

[Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study].

S. Hernandez, J. Arribas, C. Quereda, 2005, Enfermedades infecciosas y microbiologia clinica.

Pegylated interferon a 2 a plus ribavirin versus pegylated interferon a 2 b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

C. Tural, J. Mallolas, C. Quereda, 2009 .

Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

C. Tural, J. Mallolas, C. Quereda, 2009, The Journal of antimicrobial chemotherapy.

Pegylated interferon a 2a plus ribavirin versus pegylated interferon a 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

C. Tural, J. Mallolas, C. Quereda, 2009 .

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.

J. Navarro, J. Pérez-Molina, A. Rivero, 2015, The Lancet. Infectious diseases.

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

B. Clotet, M. Odriozola, J. Olalla, 2017, The Journal of antimicrobial chemotherapy.

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

I. Martínez, M. Salavert, E. Ribera, 2019, Scientific Reports.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DU

D. Podzamczer, B. Clotet, E. Negredo, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study

M. Crespo, A. Terrón, F. Gutiérrez, 2014, Journal of the International AIDS Society.

Changes in Quality of Sleep, Mood, and Other Neuropsychiatric Symptoms After Switching Dolutegravir/Lamivudine/Abacavir to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Randomized Study of People With Human Immunodeficiency Virus With Poor Sleep Quality: GESIDA 10418

H. Esteban, D. R. Crestelo, J. Cano, 2022, Open forum infectious diseases.

Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.

C. Tural, J. Mallolas, M. Crespo, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

D. Podzamczer, E. Ribera, S. Moreno, 2017, PloS one.

Effects of Sustained Viral Response in Patients With HIV and Chronic Hepatitis C and Nonadvanced Liver Fibrosis

M. Crespo, C. Quereda, J. Bellón, 2014, Journal of acquired immune deficiency syndromes.

Effect of simplification from protease inhibitors to boosted atazanavir‐based regimens in real‐life conditions

J. González-García, J. Carton, V. Asensi, 2010, HIV medicine.

Outcomes by sex following treatment initiation with darunavir/cobicistat in a large Spanish cohort of the CODAR study (GeSIDA 9316).

J. M. García de Lomas, J. De La Torre, E. Ribera, 2019, The Journal of antimicrobial chemotherapy.

Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial

J. De La Torre, J. Prada, S. Reus, 2018, The Journal of antimicrobial chemotherapy.

Do HIV-Infected Immigrants Initiating HAART have Poorer Treatment-Related Outcomes than Autochthonous Patients in Spain? Results of the GESIDA 5808 Study.

A. Royuela, I. Suárez-Lozano, J. González-García, 2010, Current HIV Research.

Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

J. Mallolas, C. Quereda, F. Pulido, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.